国药准字H20010022 医保乙类（57）基药
适应症：本品适用于敏感细菌所引起的下列感染：中耳炎、鼻窦炎、咽炎、扁桃体炎等上呼吸道感染，支气管炎、肺炎等下呼吸道感染，皮肤和软组织感染，沙眼衣原体所致的单纯性生殖器感染，非多重耐药淋球菌所致的单纯性生殖器感染。
规格：0.1gⅹ12片
0.1gⅹ24片
Zibo Wanjie Pharmaceutical Co. Ltd. was founded in 1997, in the production of controlled release preparation and antitumor drugs, the company has the most advanced production equipment and testing equipment, and the operation of the modern enterprise management system, the implementation of the whole process of drug production management.
The company aims to embrace technology, service and health, and has been committed to improving the production capacity and research ability of products, aiming at ensuring the health of patients. The firm's firm belief is to build the country's largest production base for controlled release and cancer drugs.
Zhi Tang Glipizide Controlled Release Tablets won the first prize in Shanghai science and technology progress in 2010, and won the "National Science and technology progress two prize" again in 2011.
Zibo Wanjie pharmaceutical after fifteen years of development, establish a people-oriented, market-oriented development strategy, implementation of sales management mode of science, reaction to the changes of the market quickly, continue to accumulate their own competitive advantage and achieve sustainable development of the company.
手机版
微信公众平台